Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory Days Payable Competitor Comparison
For the Pharmaceutical Retailers subindustry, Sapporo Clinical Laboratory's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sapporo Clinical Laboratory Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sapporo Clinical Laboratory's Days Payable distribution charts can be found below:
* The bar in red indicates where Sapporo Clinical Laboratory's Days Payable falls into.
Sapporo Clinical Laboratory Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory (TSE:9776) has a Days Payable of 55.69 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sapporo Clinical Laboratory and its competitors. This is near median its historical median of 59.51. Over the past decade, Sapporo Clinical Laboratory's Days Payable has ranged from 2.80 to 69.21.
Is Sapporo Clinical Laboratory's Days Payable too high?
Sapporo Clinical Laboratory's current Days Payable of 55.69 is near median its 10-year median of 59.51. Over the past 10 years, this metric has ranged from a low of 2.80 to a high of 69.21. The Healthcare Providers & Services industry median Days Payable is 57.13. Sapporo Clinical Laboratory's value of 55.69 is 2.5% below this industry median. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's Days Payable compare to competitors?
Sapporo Clinical Laboratory's Days Payable of 55.69 can be compared against companies in the Healthcare Providers & Services industry. The industry median Days Payable is 57.13. Sapporo Clinical Laboratory's value of 55.69 is 2.5% below this benchmark. Historically, Sapporo Clinical Laboratory's own Days Payable has ranged from 2.80 to 69.21 over the past decade. While the company's 10-year median is 59.51 vs. the industry median of 57.13, Sapporo Clinical Laboratory has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 57.13, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sapporo Clinical Laboratory's current Days Payable of 55.69 is 2.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sapporo Clinical Laboratory and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 57.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sapporo Clinical Laboratory's current Days Payable is 55.69, which is near median its own 10-year median of 59.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current Days Payable of 55.69. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current Days Payable is 55.69, which is near median its 10-year median of 59.51 and 2.5% below the Healthcare Providers & Services industry median of 57.13. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current Days Payable is 55.69 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?
Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued.
The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.
Key valuation signals for TSE:9776:
Days Payable: 55.69 (near median its 10-year median of 59.51)
GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
Industry Position: 2.5% below the Healthcare Providers & Services median
No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score
Get the complete analysis for TSE:9776
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9776 has been successfully added to your 
